David Riddell is a biopharmaceutical senior neuroscientist with 20 years of postgraduate experience in both academic and industrial research laboratories. They currently serve as the Head of the Molecular Pathology Biochemistry Group at Eli Lilly and Company, a position held since 2015. Previously, they held leadership roles at Wyeth Research as Associate Director, GSK as Principal Scientist, and Pfizer as Research Fellow. David earned a Bachelor's degree in Biochemistry from the University of St Andrews and a Ph.D. in Biochemistry from the University of London. Their expertise encompasses APP/Aβ biology, cholesterol biology, and Alzheimer's disease, complemented by a strong publication record and exceptional communication skills.
This person is not in the org chart
This person is not in any teams
This person is not in any offices